CDMRP Tuberous Sclerosis Complex Research Program: Clinical Translational Research Award

The Clinical Translational Research Award supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC.

Projects supported by this award mechanism may include, but not limited to:

• Understanding, preventing, and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological, behavioral, and surgical interventions
• Strategies for eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding for tumor microenvironment, TSC signaling, and mTOR interdependent pathways
• Preventing epilepsy, improving treatment, and mitigating neurodevelopmental and adverse outcomes associated with TSC-related seizures
• Developing, assessing, and testing emerging technologies including imaging and molecular therapeutic strategies, such as gene therapy, to improve outcomes in TSC

Projects that are exploratory and/or strictly animal research will not be considered for funding.

It is expected that 2 awards will be granted. 

Funding: $1,000,000 total
Duration: 3 years

Research Authority due date: 1.6.23

Pre application (required) due date: 8.6.23

Full application due date: 7.7.23